Details

Autor(en) / Beteiligte

• Perone, Ylenia
• Farrugia, Aaron J.
• Rodríguez-Meira, Alba
• Győrffy, Balázs
• Ion, Charlotte
• Uggetti, Andrea
• Chronopoulos, Antonios
• Marrazzo, Pasquale
• Faronato, Monica
• Shousha, Sami
• Davies, Claire
• Steel, Jennifer H.
• Patel, Naina
• del Rio Hernandez, Armando
• Coombes, Charles
• Pruneri, Giancarlo
• Lim, Adrian
• Calvo, Fernando
• Magnani, Luca

Titel

SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer

Ist Teil von

• Nature communications, 2019-05, Vol.10 (1), p.2115-2115, Article 2115

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Approximately 30% of ERα breast cancer patients relapse with metastatic disease following adjuvant endocrine therapies. The connection between acquisition of drug resistance and invasive potential is poorly understood. In this study, we demonstrate that the type II keratin topological associating domain undergoes epigenetic reprogramming in aromatase inhibitors (AI)-resistant cells, leading to Keratin-80 (KRT80) upregulation. KRT80 expression is driven by de novo enhancer activation by sterol regulatory element-binding protein 1 (SREBP1). KRT80 upregulation directly promotes cytoskeletal rearrangements at the leading edge, increased focal adhesion and cellular stiffening, collectively promoting cancer cell invasion. Shearwave elasticity imaging performed on prospectively recruited patients confirms KRT80 levels correlate with stiffer tumors. Immunohistochemistry showed increased KRT80-positive cells at relapse and, using several clinical endpoints, KRT80 expression associates with poor survival. Collectively, our data uncover an unpredicted and potentially targetable direct link between epigenetic and cytoskeletal reprogramming promoting cell invasion in response to chronic AI treatment. ERα breast cancer can relapse to metastatic disease following endocrine therapy. Here, the authors find that when aromatase inhibitor treatment resistance develops, epigenomic reprogramming drives Keratin-80 upregulation via SREBP1, and promotes cytoskeletal rearrangements that drive cancer cell invasion.